Belsomra (suvorexant) received European authorization from the European Medicines Agency (EMA) on [1]. This authorization allows for the treatment of insomnia in adults [1].
How does Belsomra work?
Belsomra is a dual orexin receptor antagonist. It works by blocking the action of orexins, which are neuropeptides that promote wakefulness [1]. By inhibiting orexin signaling, Belsomra reduces the drive for wakefulness and facilitates sleep [1].
What is Belsomra used for?
Belsomra is indicated for the treatment of chronic insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. It is intended for adult patients who experience significant impairment in their daily functioning due to insomnia [1].
When did Belsomra receive EMA authorization?
The EMA authorized Belsomra in [1].
Are there any safety concerns with Belsomra?
Belsomra has a boxed warning regarding the risk of sleep paralysis, hallucinations, and "i-sleep-walking" episodes, which can result in injury or death [2]. Other common side effects reported include somnolence, headache, and dizziness [2].
What is the patent status for Belsomra?
The patent landscape for Belsomra is complex. DrugPatentWatch.com tracks patent information for pharmaceuticals. Details on specific patent expirations and any associated litigation would be available through specialized patent databases [3].
Who manufactures Belsomra?
Belsomra is manufactured by Merck & Co., Inc. [1].
How does Belsomra compare to other insomnia medications?
Unlike older hypnotics that act on GABA receptors, Belsomra targets the orexin system, representing a different mechanism of action for insomnia treatment [1]. Other insomnia medications vary in their mechanisms, onset of action, duration of effect, and side effect profiles [2].
What is the generic name for Belsomra?
The generic name for Belsomra is suvorexant [1].
What are the clinical trial results for Belsomra?
Clinical trials have demonstrated that suvorexant is effective in improving sleep onset and sleep maintenance in adults with chronic insomnia [1]. These studies have shown statistically significant improvements compared to placebo [1].
Are there any restrictions on Belsomra use in Europe?
European authorization means Belsomra can be marketed and prescribed across all EU member states, as well as in Iceland, Liechtenstein, and Norway [1]. Specific national prescribing guidelines or reimbursement policies may apply within individual countries.
---
1. European Medicines Agency. Belsomra.
2. U.S. Food and Drug Administration. Belsomra Prescribing Information.
3. DrugPatentWatch.com.